Humana (HUM) has emerged as a potential turnaround candidate as Medicare margins show signs of recovery following earlier pressure from medical cost inflation and competitive bidding dynamics. The company's undervaluation narrative centers on normalized profitability in government-sponsored programs, which represent a significant revenue stream for managed care operators. This recovery thesis appeals to value-oriented investors reassessing health care stocks after a period of margin compression.
Diamond Hill Capital's Large Cap Strategy underperformed the Russell 1000 Value Index in Q2 2026, returning 3.42% net of fees versus the benchmark's 13.87% gain. The performance gap reflects structural headwinds in value investing during a period when growth and momentum dominated. Stock selection benefits in consumer staples, materials, and consumer discretionary were offset by broad underperformance in the value segment, suggesting sector rotation pressures.
The strategy's underweight in utilities and positioning in defensive consumer segments signal a cautious stance on rate-sensitive sectors. However, the inclusion of health care turnarounds like HUM reflects confidence in mean-reversion opportunities as operational pressures ease. Medicare margin recovery, if sustained, could unlock significant valuation upside for mid-cap managed care providers facing normalized cost environments.
Sector implication: Health Care rotation toward profitability recovery in payer businesses may attract value capital reallocation, though broader value strategy underperformance suggests headwinds persist. The turnaround narrative in HUM depends on whether margin recovery is structural or cyclical, with implications for defensive health care positioning.